Abstract
There are limited data regarding glucose metabolism dysregulation in multiple sclerosis (MS). Present study investigates glucose and insulin response during oral glucose tolerance test (oGTT) in MS patients. We examined 19 MS patients and 19 age, sex and body mass index (BMI) matched healthy controls. MS patients were newly diagnosed, untreated and with low Expanded Disability Status Scale (EDSS) score (1.1 ± 0.7). Plasma glucose, lactate, insulin and GLP-1 during oGTT, and fasting adipokines, lipid and inflammatory parameters were analyzed. Insulin sensitivity indices (ISI) were calculated. MS patients had comparable fasting (5.2 ± 0.3 vs. 5.0 ± 0.4 mmol/l, p = 0.05) and post-load glucose concentrations as controls. Insulin response to oral glucose load in MS was increased (p = 0.022). Insulin sensitivity was lower in MS compared to controls [ISI(Matsuda) 6.95 ± 3.44 vs. 10.60 ± 4.81, p = 0.011 and ISI(Cederholm) 49.9 ± 15.3 vs. 61.3 ± 16.3, p = 0.032]. We did not find any difference in lactate, GLP-1, total, HDL and LDL cholesterol, triglycerides, interleukin 6, tumor necrosis factor, C-reactive protein, resistin, leptin, adiponectin levels between groups. We found decreased insulin sensitivity with postprandial hyperinsulinemia in MS patients, which seems not to be related to chronic inflammation or physical inactivity. The role of hyperinsulinemia in CNS function impairment should be further investigated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adamec I, Habek M (2013) Autonomic dysfunction in multiple sclerosis. Clin Neurol Neurosurg 115(Suppl 1):S73–S78. doi:10.1016/j.clineuro.2013.09.026
Amorini AM et al (2014) Serum lactate as a novel potential biomarker in multiple sclerosis. Biochim Biophys Acta 1842:1137–1143. doi:10.1016/j.bbadis.2014.04.005
Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL (1991) Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87:2246–2252. doi:10.1172/JCI115260
Bellocco R, Jia C, Ye W, Lagerros YT (2010) Effects of physical activity, body mass index, waist-to-hip ratio and waist circumference on total mortality risk in the Swedish National March Cohort. Eur J Epidemiol 25:777–788. doi:10.1007/s10654-010-9497-6
Bergouignan A, Rudwill F, Simon C, Blanc S (2011) Physical inactivity as the culprit of metabolic inflexibility: evidence from bed-rest studies. J Appl Physiol (1985) 111:1201–1210. doi:10.1152/japplphysiol.00698.2011
Bright JJ, Walline CC, Kanakasabai S, Chakraborty S (2008) Targeting PPAR as a therapy to treat multiple sclerosis. Expert Opin Ther Targets 12(12):1565–1575. doi:10.1517/14728220802515400
Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17:819–837. doi:10.1016/j.cmet.2013.04.008
Cederholm J, Wibell L (1990) Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10:167–175
Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517. doi:10.1016/S0140-6736(08)61620-7
de la Monte SM (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 9:35–66
de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 7:45–61
Dreyer M, Matthaei S, Kuhnau J, Rudiger HW (1986) Prolonged plasma half-life of insulin in patients with a genetic defect of high affinity binding sites. Horm Metab Res 18:247–249. doi:10.1055/s-2007-1012285
Edwards LJ, Constantinescu CS (2004) A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler 10:575–581
Gong X, Xie Z, Zuo H (2008) Invivo insulin deficiency as a potential etiology for demyelinating disease. Med Hypotheses 71:399–403. doi:10.1016/j.mehy.2008.04.006
Harris MI et al (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 21:518–524
Hietaharju A, Kuusisto H, Nieminen R, Vuolteenaho K, Elovaara I, Moilanen E (2010) Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study. Eur J Neurol 17:332–334. doi:10.1111/j.1468-1331.2009.02701.x
Hussein WI, Reddy SS (2006) Prevalence of diabetes in patients with multiple sclerosis. Diabetes Care 29(8):1984–1985
Kim JH, Bachmann RA, Chen J (2009) Interleukin-6 and insulin resistance. Vitam Horm 80:613–633. doi:10.1016/S0083-6729(08)00621-3
Kraszula L, Jasinska A, Eusebio M, Kuna P, Glabinski A, Pietruczuk M (2012) Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol Neurochir Pol 46:22–28
Lagerros YT, Mucci LA, Bellocco R, Nyren O, Balter O, Balter KA (2006) Validity and reliability of self-reported total energy expenditure using a novel instrument. Eur J Epidemiol 21:227–236. doi:10.1007/s10654-006-0013-y
Liang G, Cline GW, Macica CM (2007) IGF-1 stimulates de novo fatty acid biosynthesis by Schwann cells during myelination. Glia 55:632–641. doi:10.1002/glia.20496
Licht CM, de Geus EJ, Penninx BW (2013) Dysregulation of the autonomic nervous system predicts the development of the metabolic syndrome. J Clin Endocrinol Metab 98:2484–2493. doi:10.1210/jc.2012-3104
Mahler A, Steiniger J, Bock M, Brandt AU, Haas V, Boschmann M, Paul F (2012) Is metabolic flexibility altered in multiple sclerosis patients? PLoS ONE 7:e43675. doi:10.1371/journal.pone.0043675
Martins TB, Rose JW, Jaskowski TD, Wilson AR, Husebye D, Seraj HS, Hill HR (2011) Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol 136:696–704. doi:10.1309/AJCP7UBK8IBVMVNR
Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
Oliveira SR et al (2014) Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress. Nutrition 30:268–273. doi:10.1016/j.nut.2013.08.001
Pedersen BK, Febbraio M (2005) Muscle-derived interleukin-6–a possible link between skeletal muscle, adipose tissue, liver, and brain. Brain Behav Immun 19:371–376. doi:10.1016/j.bbi.2005.04.008
Pellacani A et al (1999) Acute methylprednisolone administration induces a transient alteration of glucose tolerance and pyruvate dehydrogenase in humans. Eur J Clin Investig 29:861–867
Penesova A, Radikova Z, Cizmarova E, Kvetnanský R, Blazicek P, Vlcek M, Koska J, Vigas M (2008) The role of norepinephrine and insulin resistance in an early stage of hypertension. Ann N Y Acad Sci 1148:490–494. doi:10.1196/annals.1410.036
Petersen KF et al (2006) Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 103:18273–18277. doi:10.1073/pnas.0608537103
Regenold WT, Phatak P, Makley MJ, Stone RD, Kling MA (2008) Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci 275:106–112. doi:10.1016/j.jns.2008.07.032
Strachan MW, Deary IJ, Ewing FM, Frier BM (1997) Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20:438–445
Wada T et al (2011) Both type I and II IFN induce insulin resistance by inducing different isoforms of SOCS expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 300:E1112–E1123. doi:10.1152/ajpendo.00370.2010
Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495
Watson GS, Craft S (2006) Insulin resistance, inflammation, and cognition in Alzheimer’s Disease: lessons for multiple sclerosis. J Neurol Sci 245:21–33. doi:10.1016/j.jns.2005.08.017
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214
Zeger M et al (2007) Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 55:400–411. doi:10.1002/glia.20469
Acknowledgments
The authors appreciate the skillful technical assistance of Maria Marejkova and Jana Stibrana. This work was supported by the Slovak Research and Development Agency (grant number APVV- 0028-10).
All authors reviewed and edited the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Penesova, A., Vlcek, M., Imrich, R. et al. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis 30, 895–901 (2015). https://doi.org/10.1007/s11011-015-9665-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-015-9665-1